2. Cell Cycle/DNA Damage
    Protein Tyrosine Kinase/RTK
    Apoptosis
  3. Checkpoint Kinase (Chk)
    FLT3
    PDGFR
    Apoptosis
  4. CHIR-124

CHIR-124 

Cat. No.: HY-13263 Purity: 98.57%
COA Handling Instructions

CHIR-124 is a potent and selective Chk1 inhibitor with IC50 of 0.3 nM, and also potently targets PDGFR and FLT3 with IC50s of 6.6 nM and 5.8 nM.

For research use only. We do not sell to patients.

CHIR-124 Chemical Structure

CHIR-124 Chemical Structure

CAS No. : 405168-58-3

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solution
10 mM * 1 mL in DMSO USD 117 In-stock
Estimated Time of Arrival: December 31
Solid + Solvent
10 mM * 1 mL
ready for reconstitution
 USD 117 In-stock
Estimated Time of Arrival: December 31
Solid
5 mg USD 106 In-stock
Estimated Time of Arrival: December 31
10 mg USD 185 In-stock
Estimated Time of Arrival: December 31
50 mg USD 594 In-stock
Estimated Time of Arrival: December 31
100 mg USD 1122 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

1 Publications Citing Use of MCE CHIR-124

View All Checkpoint Kinase (Chk) Isoform Specific Products:

View All Isoforms
Chk1 Chk2

View All PDGFR Isoform Specific Products:

View All Isoforms
PDGFR PDGFRβ PDGFRα

  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

CHIR-124 is a potent and selective Chk1 inhibitor with IC50 of 0.3 nM, and also potently targets PDGFR and FLT3 with IC50s of 6.6 nM and 5.8 nM.

IC50 & Target[1]

Chk1

0.3 nM (IC50)

Chk2

697.4 nM (IC50)

PDGFR

6.6 nM (IC50)

FLT3

5.8 nM (IC50)

Cdk4/cyclin D

2.05 μM (IC50)

CDC2/cyclin B

0.5057 μM (IC50)

Cdk2/cyclin A

0.1911 μM (IC50)

bFGFR

2.01 μM (IC50)

FGFR3

1.29 μM (IC50)

VEGFR2 FLK1

0.5779 μM (IC50)

VEGFR1 FLT1

0.4636 μM (IC50)

PKCα

0.58 μM (IC50)

PKAβ I

2.25 μM (IC50)

PKCβ II

0.58 μM (IC50)

PKCγ

0.11 μM (IC50)

ERK2

4.31 μM (IC50)

PKA

0.1031 μM (IC50)

GSK3

0.0233 μM (IC50)

In Vitro

CHIR-124 is 500- to 5,000-fold less active against other cell cycle kinases, such as cyclin-dependent kinase 2/cyclin A (0.19 μM), cdc2/cyclin B (0.51 μM), and cyclin-dependent kinase 4/cyclin D (2.1 μM). CHIR-124 (≥0.9 nM) in combination with SN-38 (≥0.42 nM) causes significant synergy or >10% deviation from additivity in human cancer cell lines expressing mutant p53, and these values overlap and fall below the IC50s for SN-38 (1.2×10-7 M) and CHIR-124 (2.2×10-7 M), respectively. Moreover, CHIR-124 (100 nM) abrogates the SN-38-induced S and G2-M phase cell cycle checkpoints. CHIR-124 (200 nM) leads to a 2.5-fold elevated level of cdc25A above that of the untreated HCT116 p53−/− cells. The down-regulation of cdc25A induced by SN-38 is completely restored by concurrent or sequential treatment with CHIR-124, proving that CHIR-124 inhibits the Chk1-mediated destruction of cdc25A in whole cells[1]. CHIR-124 occupies the ATP-binding site, inhibits Chk1 (IC50, 0.3 nM) 2,000-fold more potently than Chk2 (IC50, 0.7 μM)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo

CHIR-124 (10 or 20 mg/kg, p.o.) does not have a significant effect on tumor growth when compared with the vehicle-treated group, but it potentiates the growth inhibitory effect of CPT-11 in a human breast carcinoma xenograft model. The potentiation of the tumor growth inhibitory effect of CPT-11 by CHIR-124 is associated with an increase in apoptosis induction in the tumors. CHIR-124 reverses the suppression of phospho-H3 staining induced by CPT-11, indicating abrogation of the G2-M checkpoint by CHIR-124[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

419.91

Appearance

Solid

Formula

C23H22ClN5O
CAS No.
SMILES

ClC1=CC2=C(NC(C(C3=NC4=C(C=CC=C4)N3)=C2N[[email protected]@H]5CN6CCC5CC6)=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 7.14 mg/mL (17.00 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.3815 mL 11.9073 mL 23.8146 mL
5 mM 0.4763 mL 2.3815 mL 4.7629 mL
10 mM 0.2381 mL 1.1907 mL 2.3815 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 0.71 mg/mL (1.69 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% corn oil

    Solubility: ≥ 0.71 mg/mL (1.69 mM); Clear solution

*All of the co-solvents are available by MCE.
Purity & Documentation

Purity: 98.57%

COA (253 KB) HNMR (159 KB) LCMS (97 KB)

Handling Instructions (2659 KB)
References
Kinase Assay
[1]

For the CHK1 assay, the kinase domain is expressed in Sf9 insect cells, and a biotinylated cdc25c peptide containing the consensus Chk1/Chk2 phosphorylation site (*)(biotin-[AHX]SGSGS*GLYRSPSMP-ENLNRPR[CONH2]) is used as the substrate. A dilution series of CHIR-124 is mixed with a kinase reaction buffer containing a final concentration of 30 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 2 mM DTT, 4 mM EDTA, 25 mM β-glycerophosphate, 5 mM MnCl2, 0.01% bovine serum albumin, 1.35 nM CHK1 kinase domain, 0.5 μM peptide substrate, and 1 μM unlabeled ATP, plus 5 nM 33P γ-labeled ATP (specific activity =2,000 Ci/mmol). Reactions and detection of the phosphate transfer are carried out by a radioactive method.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[1]

Severe combined immunodeficient mice harboring MDA-MD-435 tumor xenografts are randomized into the following treatment groups of 10: vehicle (captisol) alone, 5 mg/kg CPT-11, 10 mg/kg CHIR-124, 20 mg/kg CHIR-124, 5 mg/kg CPT-11 plus 10 mg/kg CHIR-124, or 5 mg/kg CPT-11 plus 20 mg/kg CHIR-124. Treatment is initiated on the day after randomization (day 1). CPT-11 is given i.p. daily (four times daily) ×5 on days 1 to 5, whereas CHIR-124 is given orally four times daily ×6 on days 2 to 7 in captisol. Percent tumor growth inhibition is defined as % T/C, where T = the treatment group mean, and C = the control group mean. In a similar study, tumors harvested from mice sacrificed on day 4 of treatment are examined for apoptosis by terminal deoxynucleotidyl transferase-mediated nick-end labeling staining and for mitotic index by immunofluorescence labeling with phospho-histone H3 antibody.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

CHIR-124405168-58-3CHIR124CHIR 124Checkpoint Kinase (Chk)FLT3PDGFRApoptosisCluster of differentiation antigen 135CD135Fms like tyrosine kinase 3Platelet-derived growth factor receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CHIR-124
Cat. No.:
HY-13263
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email address *

Phone number

 

Department *

Organization name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.